Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lower

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward bro

Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared

Spyre Therapeutics shared Phase 2 SKYWAY trial data for SPY072 in rheumatoid arthritis. The therapy

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform a

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market

US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted ea

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the

JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares

Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market s

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or m

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts

Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty va

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downg

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the

To test the hypothesis of the SPY772 program, the company also announced the initiation of SKYLIGHT,

WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Comp

This disposition follows a staggering 500% one-year stock surge.

This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 mon

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel

Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and ra

Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform a

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.36) per share which beat the analy

Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE t

Shares of Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) have been given a consensus reco

Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s stock price rose 5.7% during trading on

Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers incl

Mizuho analyst Joseph Catanzaro maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and

U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announ

WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Comp

Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However,

Spyre Therapeutics  SYRE has given investors a classic biotech dilemma. The pipeline is advancing, t

Spyre Therapeutics  SYRE has become a closely watched clinical-stage biotech stock as investors look

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but i

Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

Spyre Therapeutics falls 12% amid major insider stock sales. Explore the technical data and market s

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates

Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 mil

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raise

SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to develop

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raise

Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY

Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYW

On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreem

US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 resu